Par Pharmaceutical (PRX) Receives Patent Relating to Megace ES 625 mg/5 mL Oral Suspension
More News related to ELN
- Unusual 11 Mid-Day Movers 7/2: NAVI, AVNR, ESLR, ELN Higher; DSCO, SEPR, TIVO, ILMN Lower
- Notable Mergers and Acquisitions of the Day 7/2: JNJ/ELN, FCSX/IAAC, LSTR
- Morning Movers 7/2: ELN, QUIK, ESLR Higher; DSCO, LEA, SEPR, ILMN, MANH Lower
- ELN, QSFT, SCMP, ESLR, ENER See Volume and Upside Price Action
- Elan Corp (ELN) over all volatility at 86 into JNJ $1B deal, ELN shares up 18%
More News related to PRX
- Strativa's Development Partner, BioAlliance Pharma, Submits Loramyc(R) NDA
- Bioalliance Pharma Submits Loramyc(R) NDA to US FDA And Announces a General Shareholders' Meeting to Amend Its By-Laws
- Thomas P. Rice Elected to Board of Directors of Par Pharmaceutical Companies, Inc.
- SOHM Inc.: Rated 'Speculative Buy,' Target Price $0.33 by Beacon Equity Research
- MonoSol Rx Announces FDA Acceptance of NDA for Ondansetron Orally Dissolving Film Strip
Par Pharmaceutical Companies, Inc. (NYSE: PRX) announced that a new patent has been issued by the U.S. Patent and Trademark Office (PTO) relating to Megace ES 625 mg/5 mL oral suspension, which utilizes Elan's NanoCrystal Technology delivery system. The PTO has issued Elan Pharma International Ltd. (NYSE: ELN) U.S. Patent No. 7,101,576 containing more than 30 additional claims in connection with Par's novel formulation of megestrol acetate oral suspension, the appetite stimulant most commonly prescribed by physician.
In 2005, the U.S. Food and Drug Administration (FDA) approved Megace ES for the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of AIDS. Megace ES can be taken without regard to meals and is dosed at one-fourth the volume of the original product. Megace ES represents the first branded pharmaceutical product developed by Par to be approved for marketing by the FDA.
Related Categories
FDAStocks Mentioned
+21.68Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
